Search

The aim of the present study was to observe the effects of sorafenib on the proliferation, apoptosis and invasion of A549/DDP cisplatin-resistant lung adenocarcinoma cells cultured in vitro. The A549/DDP cisplatin-resistant lung adenocarcinoma cell strain was cultured in vitro, the cell culture group incubated in culture medium only was set as the control group (Group S0) and the four concentration gradients of sorafenib were added to the culture groups as the experimental groups: S1, 2 µmol/l; S2, 4 µmol/l; S3, 8 µmol/l; and S4, 16 µmol/l. The MTT assay was used to determine the growth inhibition rate of the cells, which were respectively subjected to sorafenib treatment for 24, 48 and 72 h. Flow cytometry was used to determine the rate of apoptosis of cells in each group following sorafenib treatment for 72 h. Furthermore, the Transwell invasion experiment was used to determine the effect on A549/DDP cell invasion following sorafenib treatment for 24 h. Based on the MTT assay, it was found that the inhibition rates of A549/DDP cisplatin-resistant lung adenocarcinoma cells in groups S1-4 following sorafenib treatment for 24 h were 4.58±2.82, 14.93±2.62, 37.58±7.13 and 58.39±8.15%, respectively. For 48 h, inhibition rates in S1-4 were 14.98±2.93, 26.28±7.31, 63.00±3.05 and 78.84±3.96%, respectively, and for 72 h, inhibition rates were 18.80±2.82, 32.71±2.55, 75.51±4.73 and 87.50±3.36%, respectively. The difference in the inhibition rates of cells among the experimental groups for the same incubation time showed statistical significance (P

to investigate the clinical features of 127 cases of the novel influenza A/H1N1 infection in Fujian Province.this study included 127 human cases with the novel influenza A/H1N1 infection in Fujian Province from May 2009 to July 2009. Data were collected and reviewed from hospital medical records. The statistical analyses were performed with SPSS 11.5.the median age of the 127 patients (55 were females) was 21 years (range 0.4 - 58). The median incubation period was 2 d (range 1 - 12 d). The typical clinical symptoms included fever, cough, sputum, and sore throat. The duration of symptoms in patients less than 5 years old and in patients more than 5 years old were (8.2 +/- 4.1) and (5.4 +/- 3.0) d respectively, the difference between these 2 groups being significant (z = 3.182, P0.01). There was also a statistically significant difference in the duration of symptoms between the high-temperature group and the low-temperature group [(6.8 +/- 3.2) vs (4.8 +/- 2.1) d, Hc = 9.729, P0.05]. The duration of symptoms in the high, the normal and the low white blood cell groups were (6.3 +/- 4.7) d, (5.4 +/- 2.8) d, and (8.5 +/- 4.2) d respectively, but the differences were not statistically significant (Hc = 4.729, P = 0.094). However, the duration of symptoms in the higher lymphocyte count group was significantly longer than that in the lower and normal lymphocyte count groups [(6.8 +/- 3.3) vs (5.4 +/- 3.4), (5.2 +/- 3.2) d, Hc = 10.105, P0.01]. Chest radiography showed patchy infiltrates in 6 patients, and their duration of symptoms was longer than patients with normal chest radiography [(8.1 +/- 5.7) vs (5.6 +/- 3.1) d], but the difference was not statistically significant (z = 1.286, P0.05). 125 patients received antiviral treatment with oseltamivir and they all had a good prognosis. There was a statistical difference in the duration of symptoms between the patients who used oseltamivir within 48 h after disease onset and patients who used the drug beyond 48 h [(4.7 +/- 2.2) vs (7.4 +/- 4.1) days, z = 4.907, P0.01]. All of the patients survived.the clinical symptoms of this series of patients with the novel influenza A (H1N1) infection appeared to be mild. There were several factors associated with longer duration of symptoms, including aged 5 years or younger, higher fever (body temperature38 degrees C), higher white blood cell count and lymphocyte count. The early use of anti-retroviral treatment with oseltamivir was useful in shortening the duration. The novel influenza A (H1N1) infection was a self-limited disease, and patients with no complications had a good prognosis.

To investigate the effects of Interleukin-18 (IL-18) on asthmatic airway inflammation.Thirty healthy adult male guinea pigs were randomly divided into 3 equal groups: asthmatic model group (Group A, undergoing intraperitoneally injection of ovalbumin (OVA) once and spraying of OVA aerosol once a day for 5 days; control group (Group B), undergoing intraperitoneally injection of OVA once and spraying of normal saline aerosol once a day for 5 days; and interleukin (IL)-18 intervention group (Group C, undergoing intraperitoneally injection of OVA once and intraperitoneal injection of IL-18 on the days 1, 3, 8. 10. 15, 17, and 19. Twenty-four hours after the final spraying or IL-18 injection the bronchalveolar lavage fluid (BALF) of the left lungs were obtained. HE staining was conducted to the sediment to examine the numbers of eosinophils, neutrophils, and monocytes. ELISA was used to detect the Th1/Th2 cytokines in the BALF. The left lungs underwent pathological examination.The number of EOS in BALF of Groups A was (98 +/- 58) x 10(6)/L, significantly higher than those of Group B, (12 +/- 10) x 10(6)/L, and Group C, (29 +/- 10) x 10(6)/L (P0.01 and P0.05). The numbers of neutrophils in the BALF of Group A was (24 +/- 16) x 10(6)/L, significantly higher than those of Group B and C [(9 +/- 7) x 10(6)/L and (10 +/- 5) x 10(6)/L respectively, both P0.05]. The concentration of IFN-gamma and IL-2 in group A were both significantly lower than those of Group B and Group C (P0.05 and P0.01). The concentration of IL-4 in Group A was significantly higher than those of Groups B and C (both P0.05). The concentration of IL-5 of Group A was significantly higher than those of Group Bs and C (both P0.01).IL-18 effectively inhibits asthmatic airway inflammation by regulating the Th1/Th2 balance.